Clinical Trial for Heavily Pre-Treated HER2+ Patients

Some hopeful news for HER2+ mbc patients who have undergone several prior therapies:

Tucatinib (ONT-380) is a small molecule inhibitor of the HER2 growth factor receptor. The drug works by targeting the HER2 "tyrosine kinase" - a link in the chain of communication that allows HER2 receptors to signal the growth of the cell. In a study of 50 women with HER2+ mbc who had progressed despite a median 5 previous treatment regimens, 27% of these heavily pretreated patients saw clinical benefit from the drug, with at least "stable disease" at 24 or more weeks after the start of treatment. These data led to two subsequent Phase Ib studies, resulting in Tucatinib earning FDA Fast-Track Status.

From: https://www.sciencedaily.com/releases/2017/01/170111091449.htm As of Jan. 2017, there is at least one recruiting clinical trial (NCT02614794) of Tucatinib for HER2+ MBC patients: https://clinicaltrials.gov/ct2/show/NCT02614794?term=tucatinib&rank=1